Table A2.
Summary of acute treatment-related toxicities.
| Type of Toxicity | Induction Phase | Surgery | HDT Phase | |
|---|---|---|---|---|
| LD/ID | HD | |||
| infection | 4 | 10 | 4 | 13 |
| gastrointestinal | 3 | 8 | ||
| hepatic injury | 3 | |||
| venous occlusive disease | 1 | |||
| cardiac | 2 | 3 | 4 | |
| renal failure | 2 | |||
| hemorrhagic cystitis | 1 | |||
| respiratory insufficiency | 1 | |||
| oral-intestinal mucositis | 5 | 12 | ||
| tumor lysis syndrome | 1 | |||
| capillary leak syndrome | 1 | 1 | ||
| hemolytic uremic syndrome | 1 | |||
| autoimmune hemolytic anemia | 1 | |||
| non-febrile seizures | 1 | |||
| intraoperative tumor rupture | 2 | |||
| severe bleeding | 4 | |||
| lymphatic fistula | 4 | |||
| Horner’s syndrome | 3 | |||
| pleural effusion | 2 | |||
| pneumothorax | 1 | |||
| cava vein thrombosis | 1 | |||
| Total | 6 | 26 | 21 | 46 |
Summary of acute treatment-related toxicities according to induction treatment split by chemotherapy intensity with low- and intermediate-dose (LD/ID) and high-dose (HD) induction schedules, the latter including stage 4 > 12 months and stage 4 ≤ 12 months but MYCN amplified tumors, the former all other treatment groups; surgical complications; and high-dose therapy (HDT).